BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 22015086)

  • 1. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
    Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
    Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
    Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S;
    Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
    Galatius S; Gustafsson F; Atar D; Hildebrandt PR
    Cardiology; 2004; 102(3):160-5. PubMed ID: 15334027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
    Aygul N; Ozdemir K; Duzenli MA; Aygul MU
    Cardiology; 2009; 112(3):168-73. PubMed ID: 18654081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
    Taniguchi T; Ohtani T; Mizote I; Kanzaki M; Ichibori Y; Minamiguchi H; Asano Y; Sakata Y; Komuro I
    J Cardiol; 2013 Jun; 61(6):417-22. PubMed ID: 23548374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
    Kotlyar E; Keogh AM; Macdonald PS; Arnold RH; McCaffrey DJ; Glanville AR
    J Heart Lung Transplant; 2002 Dec; 21(12):1290-5. PubMed ID: 12490274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
    Agostoni P; Contini M; Cattadori G; Apostolo A; Sciomer S; Bussotti M; Palermo P; Fiorentini C
    Eur J Heart Fail; 2007 Aug; 9(8):827-33. PubMed ID: 17561440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of beta-blockers on ventilation efficiency in heart failure.
    Agostoni P; Apostolo A; Cattadori G; Salvioni E; Berna G; Antonioli L; Vignati C; Schina M; Sciomer S; Bussotti M; Palermo P; Fiorentini C; Contini M
    Am Heart J; 2010 Jun; 159(6):1067-73. PubMed ID: 20569721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
    Düngen HD; Apostolovic S; Inkrot S; Tahirovic E; Töpper A; Mehrhof F; Prettin C; Putnikovic B; Neskovic AN; Krotin M; Sakac D; Lainscak M; Edelmann F; Wachter R; Rau T; Eschenhagen T; Doehner W; Anker SD; Waagstein F; Herrmann-Lingen C; Gelbrich G; Dietz R;
    Eur J Heart Fail; 2011 Jun; 13(6):670-80. PubMed ID: 21429992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
    Marazzi G; Iellamo F; Volterrani M; Caminiti G; Madonna M; Arisi G; Massaro R; Righi D; Rosano GM
    Am J Cardiol; 2011 Jan; 107(2):215-9. PubMed ID: 21129714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
    Albrecht M; Haustein KO
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
    Takayanagi R; Fujito K; Kimura K; Yamada Y
    Biol Pharm Bull; 2017; 40(6):837-843. PubMed ID: 28566627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.